ASH2019注目テーマ Late-Breaking Abstracts Session #3

55歳以上のAML寛解導入療法後の維持療法
経口アザシチジンがOS、RFSを改善 The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Andrew H. Wei（The Alfred Hospital, Melbourne, AUS）